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Viral infection of cells is sensed by pathogen recognition receptors that trigger an anti-viral 16 
innate immune response and consequently viruses have evolved countermeasures. Vaccinia 17 
virus (VACV) evades the host immune response by expressing scores of immunomodulatory 18 
proteins. One family of VACV proteins are the BTB-BACK domain containing, Kelch-like 19 
(BBK) family of predicted cullin-3 E3 ligase adaptors: A55, C2 and F3. Previous studies 20 
demonstrated that gene A55R encodes a protein that is non-essential for VACV replication 21 
yet affects viral virulence in vivo. Here we report that A55 is an NF-κB inhibitor acting 22 
downstream of IκBα degradation, preventing gene transcription and cytokine secretion in 23 
response to cytokine stimulation. A55 targets the host importin α1 (KPNA2), acting to reduce 24 
p65 binding and its nuclear translocation. Interestingly, whilst A55 was confirmed to co-25 
precipitate with cullin-3 in a BTB-dependent manner, its NF-κB inhibitory activity mapped to 26 
the Kelch domain, which alone is sufficient to co-precipitate with KPNA2 and inhibit NF-κB 27 
signalling. Intradermal infection of mice with a virus lacking A55R (vΔA55) increased VACV-28 
specific CD8+ T-cell proliferation, activation, and cytotoxicity in comparison to the WT virus. 29 
Furthermore, immunisation with vΔA55 induced increased protection to intranasal VACV 30 
challenge compared to control viruses. In summary, this report describes the first target of a 31 
poxvirus-encoded BBK protein and a novel mechanism for DNA virus immune evasion, 32 





NF-κB is a critical transcription factor in the innate immune response to infection and in 36 
shaping adaptive immunity. The identification of host and virus proteins that modulate the 37 
induction of immunological memory is important for improving virus-based vaccine design 38 
and efficacy. In viruses, the expression of BTB-BACK Kelch-like (BBK) proteins is restricted 39 
to poxviruses and conserved within them, indicating the importance of these proteins for 40 
these medically important viruses. Using vaccinia virus (VACV), the smallpox vaccine, we 41 
report that the VACV BBK protein A55 dysregulates NF-κB signalling by disrupting the p65-42 
importin interaction, thus preventing NF-κB translocation and blocking NF-κB-dependent 43 
gene transcription. Infection with VACV lacking A55 induces increased VACV-specific CD8+ 44 
T-cell memory and better protection against VACV challenge. Studying viral 45 
immunomodulators therefore expands not only our understanding of viral pathogenesis and 46 
immune evasion strategies, but also understanding of the immune signalling cascades 47 
controlling anti-viral immunity and the development of immune memory.   48 
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Introduction  49 
Virus infection is sensed by pattern recognition receptors (PRRs) that detect pathogen 50 
associated molecular patterns (PAMPs) and this triggers an innate immune response to 51 
restrict viral replication and spread. PRR-ligand binding leads to intracellular phospho-kinase 52 
signalling cascade(s) and activation of specific inflammatory transcription factors including 53 
nuclear factor kappa-light chain-enhancer of activated B cells (NF-κB), interferon regulatory 54 
factor 3, 7 or 9 (IRF3/7/9) and signal transducer and activator of transcription (STAT) 55 
proteins (1). Activation of these transcription factors controls the host innate immune 56 
response by the direct and specific transcriptional regulation of pro-inflammatory and anti-57 
viral genes. Canonical NF-κB signalling mediated via tumour necrosis factor receptor 58 
(TNFR), interleukin-1 receptor (IL-1R), retinoic acid-induced gene 1 (RIG-I)-like receptors 59 
(RLRs) and DNA sensing converges at the inhibitor of kappa B kinase (IKK) (1). 60 
Phosphorylated IKKβ in turn phosphorylates the inhibitor of NF-κB subunit alpha (IκBα) that 61 
induces its cullin-1/β-TrCP-dependent degradation (2). Under normal conditions IκBα tethers 62 
NF-κB in the cytoplasm preventing NF-κB dependent gene transcription. Free NF-κB binds 63 
to importin α1-4 (karyopherin subunit alpha (KPNA) 1-4)/importin β and translocates into the 64 
nucleus (3–6) where, following phosphorylation dependent CBP/P300- acetylation (7), it 65 
upregulates NF-κB dependent gene transcription. NF-κB-induced cytokines and chemokines 66 
then promote inflammation and immune cell recruitment to clear infection.   67 
During their evolution viruses have acquired proteins to counteract the host immune 68 
response. A prototypical example is vaccinia virus (VACV), the live vaccine used to 69 
eradicate smallpox. VACV is a member of the genus Orthopoxvirus of the Poxviridae, a 70 
family of large double-stranded DNA viruses that replicate in the cytoplasm. To evade the 71 
host immune response VACV encodes a plethora of immunomodulatory proteins including 72 
more than 10 inhibitors of NF-κB activation that function at different stages in the pathway 73 
(8). For instance, protein B14 targets IKKβ to prevent IκBα phosphorylation and degradation 74 
and subsequent p65 nuclear translocation (9). K7 was reported to co-precipitate with TRAF6 75 
5 
 
and IRAK2 to suppress TLR-dependent NF-κB activation (10), and A49 blocks β-TrCP-76 
mediated degradation of phosphorylated IκBα via molecular mimicry (11). Although ten 77 
VACV inhibitors of NF-κB have been described, others exist because a virus lacking all 78 
these inhibitors still inhibited NF-κB activation (12). Ectromelia virus, a related orthopoxvirus 79 
that causes mousepox, encodes several inhibitors of NF-κB, including protein EVM150 (13) 80 
that shares 93 % amino acid identity with VACV strain Western Reserve (WR) protein A55. 81 
A55 belongs to the BBK (Broad-Complex, Tram-Trac and Bric a Brac (BTB) and C-terminal 82 
Kelch (BACK) family of proteins (14). Interestingly, outside mammals only poxviruses 83 
encode Kelch-like proteins (15). 84 
BTB-Kelch proteins are substrate-specific adaptors for the cullin-3 ubiquitin–ligase complex 85 
and regulate modification and/or degradation of various proteins by ubiquitylation (16). 86 
Several orthopoxvirus BBK proteins co-precipitate with cullin-3 (15). The N-terminal BTB 87 
domain is essential for cullin-3 interaction and contains a conserved tertiary structure 88 
consisting of five α-helices with A1/2 and A4/5 forming α-helical hairpins, and three β-89 
strands (B1/B2/B3) forming a β-sheet. The B1/B2/A1/A2/B3 region is connected to the 90 
A4/A5 region by helix A3 and a variable linker region (17). The Kelch motif is a segment of 91 
44–56 amino acids with low overall sequence identity but eight key conserved residues, 92 
including four hydrophobic residues followed by a double glycine element, separated from 93 
two characteristically spaced aromatic residues, tyrosine and tryptophan (18). Each Kelch 94 
motif represents one β-sheet blade, and several (4-7) of these repeats can form a beta-95 
propeller (19) and a substrate binding domain. Traditionally, the Kelch domain acts as the E3 96 
ligase substrate receptor and therefore controls substrate specificity. BBK proteins through 97 
variation within their Kelch domain modulate a wide range of cellular processes including 98 
actin association/cytoskeleton organisation, cell morphology, innate immunity, and gene 99 
expression (18). For example, KLHL20 targets IKKβ to downregulate NF-κB signalling (20), 100 
while KLHL12 disrupts Wnt-β-catenin signalling through the recruitment of Dishevelled to the 101 
cullin-3 E3 ligase complex and its subsequent ubiquitylation and degradation (21).  102 
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VACV encodes three BBK proteins, A55, C2 and F3 and one BTB-only protein C5 (14). Like 103 
many other VACV immunomodulators, the VACV BBKs are expressed early during infection 104 
(22) and share low amino acid identity. This is 23.5 % between A55 and F3, and 18.7 % and 105 
18.3 % between C2 and A55 and F3, respectively. Previous studies have demonstrated that 106 
the genes A55R, F3L and C2L encode proteins that are non-essential for virus replication 107 
yet affect virulence in an intradermal mouse model (23–25). C2 and F3 modulate immune 108 
cell recruitment and proliferation in vivo (24, 25). Although the virus lacking gene A55R 109 
(vΔA55) has altered virulence, how A55 affects virulence, and whether it recruits cullin-3 or 110 
inhibits inflammatory signalling remain unknown. Thus, we investigated the effect of A55 on 111 
host innate immune signalling pathways in vitro and in vivo, and whether this modulated the 112 
immune response in vivo and/or made for a more protective vaccine.   113 
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Results  114 
A55 specifically inhibits NF-κB activation in vitro  115 
Due to the conservation between EVM150 and A55 and because other NF-κB inhibitors exist  116 
in the VACV genome (12), a role for A55 in NF-κB signalling was investigated. HEK293T’s 117 
were co-transfected with a plasmid expressing A55 and plasmids encoding NF-κB-Luc and 118 
pTK-Renilla. Cells were stimulated with TNFα or IL-1β or left unstimulated and Firefly 119 
luciferase was measured alongside Renilla as an internal control. Empty vector (EV) and the 120 
human BBK KLHL12 were used as negative controls, while B14 was included as a known 121 
NF-κB inhibitor. A55 expression inhibited NF-κB activity in response to both IL-1β and TNFα 122 
compared to the EV and KLHL12 controls (Fig. 1A-B) in a dose-dependent manner (Fig. 123 
1C). A55 also inhibited expression of endogenous NF-κB-responsive genes in response to 124 
TNFα-stimulation. For instance, transcription of IL-8 (measured by RT-qPCR) and secretion 125 
of CXCL10 (measured by ELISA) were both inhibited by A55 (Fig. 1D-E). In contrast, A55 126 
did not inhibit the JAK-STAT (ISRE-luc) or activator protein 1 (AP-1) promoter activity in 127 
response to interferon (IFN)α or phorbol myristic acid (PMA), respectively (Fig. 1F-G). VACV 128 
protein C6 inhibited IFNα-stimulated ISRE activity as reported (Fig. 1G) (26). The ability of 129 
A55 to inhibit both IL-1β and TNFα-induced stimulation of NF-κB signalling suggested that it 130 
acts at or below TAK1 phosphorylation where the IL-1R and TNFR pathways converge. 131 
Inhibitory activity of A55 is mapped to NF-κB activation downstream to IκBα 132 
degradation  133 
The NF-κB pathway can be activated by overexpression of proteins acting at specific stages. 134 
Thus, to map where A55 inhibits the pathway, plasmids encoding TRAF6, TRAF2, 135 
TAK1/TAB1, IKKβ or p65 were co-transfected into HEK293Ts along with pcDNA4/TO-nTAP-136 
coA55R. Pathway activation was measured by NF-κB-luciferase expression as above. EV 137 
and KLHL12 or B14 were used as negative and positive controls, respectively. B14 inhibited 138 
at IKKβ (9) (Fig. 2A-D), whilst KLHL12 was not inhibitory (Fig. 2A-E). A55 expression 139 
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inhibited NF-κB activity in response to TRAF2, TRAF6, TAK1, IKKβ and p65 (Fig. 2A-E), and 140 
in the latter case the degree of inhibition increased with greater expression of A55 (Fig. 2E). 141 
Therefore, A55 acts at the level of p65 or downstream.  142 
Under resting conditions IκBα tethers NF-κB in the cytoplasm but upon stimulation IκBα is 143 
phosphorylated by IKKβ, ubiquitylated and degraded by the β-TrCP/cullin-1 E3 ligase 144 
complex and proteosome (27). Free p65 phosphorylated at S536 translocates into the 145 
nucleus where it undergoes phosphorylation at S276. This facilitates recruitment of p-RNAP 146 
II and p300 (7) and formation of the enhancersome to initiate gene transcription. To map the 147 
inhibitory mechanism of A55 further, HEK293T-REx cell lines with EV or vectors expressing 148 
B14 or A55 were stimulated with TNFα and IκBα levels were analysed. As expected, B14 149 
inhibited TNFα-induced degradation of IκBα (Fig. 3A-B). However, although expression 150 
levels of A55 and B14 were similar, A55 did not prevent IκBα degradation (Fig. 3A-B). 151 
Consistent with reporter gene assays, this indicated that A55 acted at or below p65 release. 152 
Phosphorylation is key to the transcriptional activity of p65. To determine if A55 regulates 153 
phosphorylation of p65, HEK293T-REx cells expressing A55 were stimulated with TNFα and 154 
the levels of p-p65 S536 and S276 were analysed. While p-p65 S536 levels were 155 
comparable, A55 abrogated S276 phosphorylation (Fig. 3C), which is a nuclear event (7). 156 
This suggests that A55 may inhibit S276 phosphorylation directly, or indirectly by preventing 157 
nuclear translocation of p65.  158 
To explore whether A55 inhibits nuclear translocation of p65, HeLa cells transfected with 159 
Flag-tagged EV, B14, A55 or C6 were stimulated with TNFα and the subcellular localisation 160 
of p65 was analysed by immunofluorescence (Fig. 4A). Cells were co-stained with anti-Flag 161 
and p65, and DAPI to stain DNA, and the number of cells exhibiting nuclear exclusion of p65 162 
were numerated (Fig. 4B). As expected, almost 100% of the EV untreated cells exhibited 163 
nuclear exclusion of p65 in comparison to 10% of EV-stimulated cells (Fig. 4B) and B14 164 
prevented nuclear translocation of p65, while protein C6 did not (Fig. 4B). In comparison, 165 
A55 inhibited translocation of p65 in 62% of transfected cells following stimulation (Fig. 4B). 166 
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Collectively, this maps the inhibitory activity of A55 prior to nuclear translocation of free NF-167 
κB but after IκBα degradation.  168 
A55 targets importins to inhibit NF-κB activation 169 
The nuclear translocation of NF-κB p65 is regulated by importin-α 1-4/importin-β shuttling, 170 
dependent upon cell type and stimulus (3–5). To determine if A55 targets the nuclear 171 
importins the interaction of A55 and importins was investigated following 172 
immunoprecipitation of Flag-tagged KPNA1, 2 or 3 from transfected HEK293Ts that were 173 
infected with WT VACV WR. Co-immunoprecipitation (co-IP) of A55 was tested using an 174 
A55 specific antibody (23). A55 co-precipitated with KPNA2, but not KPNA1 or 3, whereas 175 
C6 was not co-precipitated (Fig. 5A). Consistent with this, endogenous KPNA2, but not 176 
KPNA1, co-precipitated with transfected Flag-tagged A55 (Fig. 5B). KPNA2 is required for 177 
p65 translocation, and therefore the interaction of p65 and KPNA2 was investigated in the 178 
presence of A55 or B14. Transfected HA-p65 was immunoprecipitated and the levels of co-179 
precipitated KPNA2 were reduced in the presence of A55 (Fig. 5C) suggesting A55 may 180 
block interaction of KPNA2 and p65. As A55 is a predicated BBK E3 ligase adaptor, the 181 
levels of KPNA2 following infection with the WT VACV strain WR (vA55), a mutant lacking 182 
gene A55R (vΔA55), or the revertant virus with A55R inserted back into vΔA55 and under its 183 
endogenous promoter were investigated. Notably, the levels of KPNA2 did not alter during 184 
infection or transfection (Fig. 5D).  185 
A55 inhibits NF-κB in a Kelch-dependent manner independent of cullin-3 binding  186 
Typically, BBKs recruit cullin-3 via their BTB domain and their substrates to the cullin-3 E3 187 
ligase complex via their C-terminal Kelch domain. Therefore, a possible interaction between 188 
A55 and cullin-3 was investigated and this showed that endogenous cullin-3 co-precipitated 189 
with A55, but not with B14 (Fig. 6A). This interaction was confirmed by reciprocal IP of 190 
overexpressed Myc-tagged cullin-3 or cullin-5 (Fig. 6B). Subdividing A55 into its BTB and 191 
Kelch domain (Fig. 6C) showed that precipitation of endogenous cullin-3 was achieved by 192 
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the BTB domain but not Kelch domain of A55 (Fig. 6D). In contrast, the Kelch domain was 193 
sufficient to co-IP endogenous KPNA2 (Fig. 6E). To determine if the Kelch domain mediated 194 
inhibition of NF-κB activation, HEK293T-REx cells expressing the full length A55 or the BTB-195 
BACK or Kelch domains separately were stimulated with IL-1β or TRAF6 co-transfection and 196 
NF-κB luciferase activity was measured. Despite higher levels of BTB-BACK expression 197 
(Fig. 6G) only the Kelch domain inhibited IL-1β- and TRAF6-induced NF-κB activation (Fig. 198 
6F). We next tested if either domain was sufficient to prevent NF-κB p65 nuclear 199 
translocation. HeLa cells transfected with Flag-tagged C6, A55, A55 BTB or A55 Kelch were 200 
stimulated with TNFα and the subcellular localisation of p65 was analysed by 201 
immunofluorescence as before. Interestingly, both domains alone appeared to inhibit p65 202 
translocation following TNFα stimulation as efficiently as full length A55 (Fig. 7A-B). 203 
However, the inhibitory activity of A55 BTB-BACK correlated with induction of cellular 204 
vacuolarisation (Fig. 7C) compromising the conclusion that this was indirect inhibition by 205 
BTB-BACK. Thus, A55 can inhibit NF-κB activation in a Kelch-dependent and cullin-3-206 
independent manner. 207 
A55 inhibits CD8+ T-cell proliferation and activation in the acute phase of infection  208 
The potential role of A55 as an immunomodulator was investigated next by measuring the 209 
immune cell number and activation status, as well as immunological memory in C57BL/6 210 
mice infected intradermally with vA55, vΔA55 and vΔA55Rev (28, 29). 211 
As expected, the lesion size was increased upon infection with vΔA55 compared to control 212 
viruses (data not shown) (23). On day 7 p.i. the absolute cell number of immune cells in the 213 
spleen (Fig. 8A) and draining lymph nodes (DLN) (Fig. 8B) were counted. The total splenic 214 
and DLN cell number, and CD8+ T-cells and macrophages in these organs, were 215 
significantly increased during infection with vΔA55 compared to control viruses, while no 216 
significant changes were observed for CD4+ T-cells, neutrophils or NK cells (Fig. 8A-B). 217 
CD8+ T-cells also showed enhanced activation (increased CD69 expression) at day 7 p.i. 218 
(Fig. 8C-D) and this correlated with increased VACV-specific CD8+ T-cells at day 7 and 28 219 
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p.i. (Fig. 8E). In contrast, no increase in NK cell or CD4+ T-cell activity was observed (Fig. 220 
8C-D). Interestingly, the increase in CD8+ T-cell activation upon infection with vΔA55 was 221 
still apparent at day 28 p.i (Fig. 8C-E) whereas T cell activation in the WT had returned to 222 
basal level. Therefore, we tested if loss of A55 enhanced CD8+ T-cell memory and if so, if 223 
immunisation with vΔA55 provides better protection to challenge.  224 
A55 deletion enhances CD8+ T-cell memory and provides protection to VACV 225 
challenge 226 
Strong CD8+ T-cell immunological memory is desirable following vaccination (30). To test if 227 
A55 modulates immunological memory the killing activity of splenic CD8+ T-cells and NK 228 
cells was assessed at day 28 p.i. with vA55, vΔA55 or vΔA55Rev. Killing of VACV-infected 229 
EL4 cells by splenic T-cells isolated 28 days p.i. was significantly increased for all three 230 
infected groups versus mock control (Fig. 9A). EL4-killing was also greater with CD8+ T-cells 231 
isolated from mice immunised with vΔA55 in comparison to control viruses (Fig. 9A). Notably 232 
T-cell mediated killing was reduced to basal levels by the addition of an anti-CD8 antibody, 233 
showing cytolysis was CD8+ T-cell specific (Fig. 9B). In contrast, no differences between the 234 
vA55 or vΔA55 groups were observed in the ability of NK cells to kill VACV-infected P815 235 
cells following immunisation (Fig. 9A).   236 
To test if vΔA55 makes for a better vaccine, mice infected intradermally with vA55, vΔA55 or 237 
vA55Rev were challenged intranasally at day 28 p.i. with vA55. Weight loss and viral titres in 238 
the lungs were quantified on days 1 and 4 p.i. Weight loss was significantly reduced from 239 
day 3 to day 7 p.i. in vΔA55 immunised mice compared to control groups (Fig. 9C). This was 240 
accompanied by a decrease in viral titre in the lungs of vΔA55 immunised mice at day 4 p.i. 241 
(Fig. 9D). Taken together these data show that vΔA55 immunised mice are better protected 242 
following intranasal challenge and clear viral infection quicker, making for a more efficacious 243 




During evolution with their hosts, viruses have evolved strategies to evade or suppress the 246 
host immune system. The study of virus-encoded proteins that modulate the immune 247 
response (immunomodulators or immunevasins) has increased our understanding of not 248 
only virus immune evasion and pathogenesis, but also of cellular signalling pathways and 249 
regulators of the immune response to infection. VACV encodes scores of immunomodulators 250 
and a mutant virus lacking one of these, called A55, increased immunopathology following 251 
intradermal infection (23). This observation, and the report that the orthologue of A55 in 252 
ectromelia virus, EVM150, inhibited NF-κB (13), led us to investigate the function of A55 253 
further, and the consequence of A55 expression on the NF-κB signalling pathway in vitro 254 
and the immune response to infection in vivo. This report shows A55 targets the cellular 255 
importin KPNA2 to dysregulate p65 translocation and restrict NF-κB activation. Furthermore, 256 
immunisation with a virus lacking A55 induced a stronger CD8+ T-cell response to VACV and 257 
better protection against VACV challenge. 258 
Consistent with a report on EVM150 (13), data presented show that A55 inhibits cytokine 259 
expression and NF-κB-luciferase activity in response to TNFα and IL-1β, by preventing p65 260 
translocation but without affecting IκBα levels. This suggested a possible modulation of 261 
cellular factors needed for p65 translocation. Consistent with this, A55 co-precipitated with 262 
KPNA2, part of the importin complex. Further the interaction seen between KPNA2 and p65 263 
was reduced in the presence of A55, indicating that A55 may disrupt KPNA2-p65 complex 264 
formation to inhibit p65 translocation. This observation is relevant to understanding which 265 
KPNAs control NF-κB p65 translocation.  266 
Humans encode a family of importins of which KPNA1-4 and KPNA6 are implicated in 267 
regulating NF-κB signalling. The interaction of KPNA1-3 with NF-κB was identified from an in 268 
vitro screen using importins purified from bacteria (5), and an interaction of KPNA2-4 with 269 
p65 was observed both in vitro and in vivo, and the KPNA2/p65 interaction was NLS-270 
dependent (4). Conversely, KPNA2/p65 binding was not observed using recombinant protein 271 
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from insect cells, and the authors suggested that KPNA3/4 interaction is more biologically 272 
relevant (4). However, this evidence may only suggest that KPNA2 does not interact directly 273 
with p65 in the absence of pathway stimulation or post-translation modification (4), and 274 
KPNA2/p65 binding was enhanced following TNFα stimulation (4). An siRNA screen of the 275 
impact of importins on p65 translocation following TNFα stimulation indicated that KPNA2 276 
and KPNA6 contribute the most (3). More recently siRNA mediated knockdown of KPNA2 277 
was shown to impair p65 translocation and NF-κB-dependent gene expression in rat 278 
pancreatic Acinar cells (6). Collectively, the literature suggests multiple importins regulate 279 
p65 translocation, with KPNA2 playing a leading role. KPNA redundancy may explain why 280 
A55-mediated inhibition of p65 translocation is incomplete, and why its inhibition is less 281 
efficient than B14, which targets IKKβ (9), or A49, which targets β-TrCP (11). 282 
Targeting of importins to dysregulate cellular signalling has been reported for RNA viruses 283 
(31–34). For instance, Japanese encephalitis virus NS5 targets KPNA2-4, with binding of 284 
KPNA3/4 preventing IRF3 translocation (32). Hepatitis C virus NS3/4A restricts IRF3 and 285 
NF-κB translocation by targeting KPNAB1 (33), and Hantaan virus nucleocapsid protein 286 
inhibits p65 translocation and co-precipitated with overexpressed KPNA1, 2 and 4 (34). 287 
However, this report is the first describing specific targeting of KPNA2 to disrupt p65-KPNA2 288 
complex formation and subsequently NF-κB signaling and reinforces the importance of 289 
KPNA2 in NF-κB translocation. A55 lacks a canonical NLS and is cytoplasmic, and therefore 290 
is unlikely to be a KPNA2-dependent cargo, but rather functions in the cytoplasm. Whilst 291 
targeting KPNA2 reduces NF-κB signalling, it may also have other consequences on nuclear 292 
shuttling that may contribute to the in vivo phenotype of vΔA55. The A55 N-terminal BTB 293 
domain, which binds cullin-3 may also contribute to this phenotype. 294 
Although the inhibition of NF-kB activation by A55 depends on the A55 Kelch domain and is 295 
independent of cullin-3 binding, the BTB-BACK domain likely also has an important function. 296 
To start to address this, the co-crystal structure of the A55 BTB-BACK domain bound to 297 
cullin-3 was determined and revealed an overall interaction that is conserved between cullin-298 
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3 and other cellular binding partners such as KLHL3, a human BTB (35). Nonetheless, the 299 
affinity of A55 BTB-BACK for cullin-3 was much higher than for other cullin-3 binding 300 
partners, suggesting that A55 would be an effective competitor for the interaction of cullin-3 301 
and its binding partners (35).  302 
Data presented here are consistent with that for the ectromelia virus orthologue of A55, 303 
EVM150, with one exception. Both proteins co-precipitated with cullin-3 via an N-terminal 304 
BTB domain, and both inhibited NF-κB activation in a cullin-3-independent manner. With 305 
EVM150, however, inhibition of p65 translocation and NF-κB signalling was reported to 306 
require only the BTB domain, and the Kelch domain lacked this inhibitory activity (13). In 307 
contrast, the A55 Kelch domain mediated co-precipitation with KPNA2 and inhibition of NF-308 
κB activation, and this fits with inhibition being cullin-3-independent. Discrepancies might 309 
reflect precisely where A55 and EVM150 were sub-divided, subtle differences in amino acid 310 
composition, or changes in solubility and expression levels of the BTB and Kelch domains. 311 
Concerning these possibilities, firstly, we expressed the A55 BTB domain as amino acids 1-312 
251, which includes the BACK and 3-box domain. The Kelch domain was expressed as 313 
amino acid 252-565. In contrast, the study of EVM1550 expressed the BTB domain only, 314 
lacking both the BACK and 3-box domain. Secondly, we observed that the A55 BTB-BACK 315 
domain expressed at higher levels than either the Kelch domain or full-length protein and 316 
this was adjusted for the reporter assays by modulating the amount of plasmid transfected. 317 
Finally, expression of A55 BTB-BACK induced cellular vacuolarisation, a phenotype 318 
associated with cullin-3 depletion (36). Therefore, the apparent inhibitory activity of A55 319 
BTB-BACK, and potentially of EVM150-BTB, may be due to overexpression and cullin-3 320 
saturation leading to inhibition of p65 translocation due to loss of cell viability. Whilst the 321 
Kelch domain alone was sufficient to inhibit NF-κB signalling, the ability of A55 to bind cullin-322 
3 might still affect NF-κB signalling during infection, where protein levels may be lower and 323 
other viral proteins are present, and particularly in vivo, where NF-κB activation needs to be 324 
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counteracted in different cell types. The existence and conservation of several poxviral BBKs 325 
suggest that they play an important role during infection.  326 
Inflammation and expression of NF-κB-dependent cytokines are important for the 327 
development and proliferation of effector and memory T-cell populations (37). Consistent 328 
with this, deletion of the NF-κB inhibitor A55 modulated the immune response during acute 329 
infection and led to enhanced VACV-specific CD8+ T-cell memory. This is reminiscent of a 330 
VACV mutant lacking NF-κB inhibitor N1 causing enhanced CD8+ T-cell memory and 331 
effector function (38). However, to confirm that it is the ability of A55 to inhibit NF-κB 332 
activation that results in the enhanced CD8+ T-cell memory, rather than other functions of 333 
the A55 protein, it will be necessary in the future to study the immunogenicity of a virus 334 
expressing a mutant A55 protein that is no longer able to bind to cullin-3. Understanding the 335 
signals derived from acute infection that mediate development of immunological memory are 336 
key to effective future vaccine design. VACV mutants lacking specific immunomodulators are 337 
useful tools to understand the mechanisms underlying and controlling immunological 338 
memory, but also suggest ways to produce VACV-based vaccines that induce enhanced 339 
CD8+ T-cell memory.  340 
In conclusion, this report shows that VACV protein A55 inhibits NF-κB activation, and is the 341 
eleventh VACV encoded NF-κB inhibitor (8). Despite the presence of other NF-κB inhibitors, 342 
loss of A55 gives an in vivo phenotype leading to enhanced CD8+ T-cell memory and better 343 
protection against re-infection. Mechanistically, A55 co-precipitates with KPNA2 via its Kelch 344 
domain to disrupt p65-KPNA2 interaction and impair p65 nuclear translocation.  345 
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Material and methods  346 
Ethics statement  347 
This work was conducted under license PPL 70/8524 from the UK Home Office according to 348 
the Animals (Scientific Procedures) Act 1986.  349 
Cells, plasmids, reagents and viruses  350 
All reagents were purchased from Sigma unless otherwise stated. BSC-1 (ATCC) and 351 
HEK293T cells were grown in Dulbecco’s Modified Eagle’s medium (DMEM) high glucose 352 
(Gibco), HeLa cells (ATCC) were grown in MEM (Gibco) and EL4 (H-2b; ATCC) and P815 353 
(ATCC) cells were grown in RPMI (Gibco). All media were supplemented with 10 % foetal 354 
bovine serum (FBS; Pan Biotech), non-essential amino acids (NEAA) and 50 μg/ml 355 
penicillin/streptomycin (P/S) at 37 ⁰C in a 5 % CO2 atmosphere. All plasmids used and those 356 
constructed during this study are listed in Table 1. Plasmids were generated using 357 
conventional restriction enzyme digest and ligation using the primers with restriction enzyme 358 
sites listed in Table 1. VACV strain WR recombinants vA55 (plaque purified wild type), 359 
vΔA55 (A55 deletion mutant) and vΔA55Rev (revertant virus with A55R re-inserted into 360 
vΔA55) were described (23). Infectious virus titres (plaque-forming units [p.f.u.]/ml) were 361 
determined by plaque assay on BSC-1 cells.  362 
HEK293T-REx, pLDT and pCW57 cell line generation  363 
HEK293T-REx cells were constructed using the pcDNA4/TO plasmids in Table 1 along with 364 
plasmid pcDNA6-TR encoding the tetracycline inducible promoter repressor. After 365 
transfection into HEK293T using LT1 transfection reagent, cells were selected using 366 
blasticidin and zeocin, following the manufacturer’s instructions (Invitrogen). The pCW57 or 367 
pLDT plasmids listed in Table 1, along with the EV as a control, were co-transfected with the 368 
packaging (pCMV-PACK) and envelope (pCMV-ENV) plasmids for lentivirus production in 369 
HEK293Ts or HEK293T TetR (pLDT-TetR transduced HEK293T), respectively, using LT1 370 
transfection reagent (MirusBio). After 48 h the medium was filtered and transferred to fresh 371 
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monolayers of HEK293T cells and 3 d later 2 μg/ml puromycin (Invivogen) was added. 372 
Transduction and expression was confirmed by the addition of 2 μg/ml doxycycline and 373 
immunoblotting of cell lysates. 374 
Luciferase reporter assay 375 
HEK293T cells were transfected with 100 ng pcDNA4/TO-EV, 100 ng pcDNA4/TO-nTAP-376 
coA55R, 25 ng pcDNA4/TO-nTAP-coA55R-BTB, 100 ng pcDNA4/TO-nTAP-coA55R-Kelch, 377 
100 ng pcDNA3-Flag-KLHL12, 20 ng pcDNA3-Flag-coB14R (9) or 20 ng pcDNA4/TO-cTAP-378 
C6L (39) along with 10 ng of plasmid pTK-Renilla (pRL-TK, Promega) and 45 ng of pLUC-379 
NF-κB (R. Hofmeister, University of Regensburg, Germany), pLUC-AP-1 (Andrew Bowie, 380 
Trinity College Dublin) or pLUC-ISRE (Promega) using LT1 transfection reagent (MirusBio 381 
Ltd). All conditions were transfected with equal amount of total plasmid DNA by 382 
supplementing with pcDNA/TO-EV. Simultaneously, where stated, plasmids encoding 383 
TRAF2, TRAF6 (Andrew Bowie, Trinity College Dublin), TAK1 and TAB1, IKKβ (Alain 384 
Chariot, University of Leige) or p65 were co-transfected. After 24 h cells were stimulated with 385 
20 ng/ml TNFα, 15 ng/ml IL-1β, 1000 U interferon (IFN)α (all Peprotech) or 10 ng/ml phorbol 386 
12-myristate 13-acetate (PMA) for 6 h. Cells were lysed in Passive lysis buffer (Promega) 387 
and Firefly/Renilla luciferase activity was measured using a FLUOstar Omega plate reader 388 
(BMG Labtech). Relative luminescence levels were calculated by normalising firefly 389 
luminescence to Renilla luminescence and are represented as relative to the non-stimulated 390 
EV condition.  391 
RT-qPCR  392 
RNA extraction, cDNA synthesis and RT-qPCR were carried out as described (40). qPCR 393 
used primers for IL-8 (AGAAACCACCGGAAGGAACCATCT and 394 
AGAGCTGCAGAAATCAGGAAGGCT) and GAPDH (TCGACAGTCAGCCGCATCTTCTTT 395 
and ACCAAATCCGTTGACTCCGACCTT).  396 
ELISAs  397 
18 
 
HEK293T-REx cell lines were starved for 6 h in DMEM without supplements before 398 
stimulating for 18 h with 20 ng/ml TNFα. CXCL10 in the medium was measured using 399 
CXCL10/IP-10 DuoSet ELISA kit (R&D Systems) and the FLUOstar Omega plate reader 400 
(BMG Labtech). Experiments were carried out in triplicate and measured with technical 401 
repeats.  402 
Translocation assay and immunofluorescent staining  403 
HeLa cells were transfected with plasmids encoding N-terminal TAP-tagged C6, B14 or A55 404 
using the LT1 transfection reagent (MirusBio). After 24 h cells were starved in DMEM without 405 
serum for 3 h, followed by stimulation with 40 ng/ml TNFα for 30 min. Cells were washed 3 406 
times in ice-cold PBS and processed for immunofluorescence staining and imaging as 407 
described (39). Rabbit anti-Flag and mouse anti-p65 were used as the primary antibodies 408 
and goat anti-rabbit 546 and donkey anti-mouse 488 as the secondary antibodies. Images 409 
were analysed using the Zeiss Zen microscope software and ImageJ. Experiments were 410 
performed in triplicate and carried out three times. For each repeat, 100 flag-positive cells 411 
were counted for each condition and the number of cells showing clear nuclear exclusion of 412 
p65 were counted to calculate the percentage.  413 
Co-immunoprecipitation  414 
HEK293T-REx cells were induced with 2 µg/ml doxycycline for 24 h and lysed in either 415 
phosphate-buffered saline supplemented with 0.5 % NP40 (IGEPAL CA-630) and protease 416 
inhibitor, or RIPA buffer (50 mM Tris pH 8.0, 150 mM NaCl, 0.5 M EDTA, 1 % NP40, 0.5% 417 
sodium deoxycholate, 0.1 % SDS supplemented with protease inhibitor) where stated. 418 
Proteins were immunoprecipitated as described (39) with M2 Flag-beads, HA-beads or 419 
Fastflow G-Sepharose (GE Healthcare) incubated previously with mouse monoclonal anti-420 
Myc-Tag clone 9B11 (CST; #2276) at 1:50. After the final wash, beads were incubated in 4x 421 
sample loading dye (LDS; Tris 0.5 M pH 6.8, 40 % glycerol, 6 % SDS, 1 % bromophenol 422 
blue and 0.8 % β-mercaptoethanol) and analysed by immunoblotting.  423 
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Immunoblotting and Antibodies  424 
Samples were prepared by the addition of LDS, boiled and then separated by 425 
electrophoresis in a SDS-polyacrylamide gel in Tris-glycine SDS (TGS) buffer (20 mM Tris, 426 
192 mM glycine, 1 % (w/v) SDS) before transferring to a nitrocellulose membrane (GE 427 
Healthcare) in Tris glycine (TG) buffer (20 mM Tris-HCl pH 8.3, 150 mM glycine) using the 428 
Turboblot system (BioRAD). Membranes were blocked in 5 % milk in Tris-buffered saline (10 429 
mM Tris, 150 mM NaCl) pH 7.4 with 0.1 % (v/v) Tween-20 (TBS-T) for 60 min before 430 
incubating with the primary antibody overnight at 4 ⁰C. Primary antibodies: rabbit polyclonal 431 
anti-KPNA2 (Abcam, ab70160), rabbit polyclonal anti-IκBα (CST, #9242), anti-p65 S536 432 
(CST, S3010S), anti-p65 S276 (Santa Cruz, sc-101749), rabbit monoclonal anti-cullin-3 433 
clone EPR3195 (Abcam, ab108407), anti-Flag (F7425), mouse anti-myc 9B11 (CST, #2276), 434 
anti-tubulin (Millipore; 05-829), mouse monoclonal anti-KPNA1 187.1 (Santa Cruz, sc-435 
101292), anti-p65 clone F-6 (Santa Cruz, sc-8008), anti-phospho-IκBα (CST, #9246) and 436 
antibodies to VACV proteins rabbit polyclonal anti-C6 (39), or A55 (23), or mouse 437 
monoclonal D8 clone AB1.1 (41). Membranes were washed 3 times in TBS-T before 438 
incubating with secondary antibodies for 1.5 h. Secondary antibodies were goat anti-rabbit 439 
IRDye 800CW (926-68032211; LiCOR) and goat anti-mouse IRDye 608LT (926-68020; 440 
LiCOR) or, for immunoprecipitated samples, biotin-anti-mouse light chain followed by 441 
streptavidin IRDye 680LT (926-68031; LiCOR) was used. Finally, membranes were washed 442 
3 times in TBS-T, dried and imaged using the LiCOR system and Odyssey software. 443 
Densitometry was calculated using ImageJ.  444 
Intradermal mouse model of infection and intranasal challenge experiments  445 
Female C57BL/6 mice 6-8 weeks old (n=5), were infected with 5 × 103 p.f.u. in both ear 446 
pinnae with VACV strains vA55, vΔA55 and vΔA55Rev that had been purified by sucrose 447 
density gradient centrifugation. Lesion size was measured daily with a micrometer until day 448 
21. At day 28 p.i. mice were infected intranasally with 107 p.f.u. VACV and their weight 449 
measured daily for 7 days.  450 
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Isolation of cell populations and staining for flow cytometry 451 
Cells from spleen and lymph nodes were isolated by grinding the organ through a 40 µm 452 
nylon cell strainer to create single-cell suspensions. Splenocytes were treated with red blood 453 
cell (RBC) lysis buffer to remove contaminating RBCs. Single cell suspensions were stained 454 
with fluorescently-labelled antibodies: CD3 (clone 145-2C11), CD4 (GK1.5), CD8 (5H10-1), 455 
CD45R (RA-6B2), NK1.1 (PK136), CD69 (H1.2F3), F4/80 (BM8), Ly6G (1A8) and CD16/32 456 
(2.4G2) purchased from BD Biosciences or Biolegend. These antibodies were purified or 457 
conjugated with PerCP/cy5.5, FITC, APC/Cy7, APC, PE-Cy7, PE or BV650. Isotype controls 458 
were used as negative controls. Live cells were discriminated with a fixable LIVE/DEAD stain 459 
(Life Technologies). Stained cells were analysed by flow cytometry on a BD LSR Fortessa 460 
(BD Biosciences), and data were analysed with FlowJo software (Tree Star Inc.).  461 
DimerX assay to detect VACV-specific CD8+ T cells 462 
The DimerX assay was performed according to the manufacturer's instructions (BD 463 
Biosciences) using H-2Kb:Ig fusion proteins and B820 peptide (TSYKFESV), as described 464 
(38).  465 
CD8+ T-cell and NK cell killing assay  466 
Cytotoxic T lymphocyte activity was assayed by 51Cr-release assay as described (38). 467 
VACV-infected EL4 cells or P815 cells were used as targets for VACV-specific cytotoxic T 468 
lymphocyte cell lysis or VACV-specific natural killer (NK) cell cytotoxicity, respectively.  469 
Statistics  470 
All experiments were carried out in triplicate and are representative or an average of at least 471 
three independent experiments unless stated. Data are the mean +/- SD, or, for in vivo data, 472 
+/- SEM. All assays were analysed by unpaired T-test with GraphPad Prism 6 Software 473 
where p<0.05 = *, p<0.01 = **, p<0.001 = *** and p<0.0001 = ****.  474 
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Figure Legends  602 
Fig. 1. A55 inhibits NF-κB dependent signalling. (A, B) HEK293T cells were 603 
transfected with pLuc-NF-κB and pRL-TK (Methods) and plasmids expressing Flag-604 
tagged KLHL12, B14 or A55 or empty vector (EV). After 24 h cells were stimulated 605 
with (A) 15 ng/ml IL-1β or (B) 20 ng/ml TNFα for 6 h. Cell lysates were prepared and 606 
the fold increase in luciferase activity relative to Renilla activity was determined. In 607 
parallel, cell lysates were analysed by SDS-PAGE and immunoblotting with anti-Flag 608 
or anti-α-tubulin to determine protein expression levels from unstimulated samples. 609 
Data are representative of three independent experiments. Statistical significance 610 
compares EV stimulated with test sample. (C). As in (A) using increasing plasmid 611 
concentration of pCNDA4/TO-nTAP A55 at 25, 75 and 150 ng. Statistical 612 
significance compares EV stimulated with A55 stimulated. (D). HEK293T pCW57 613 
stable cell lines inducibly expressing C6, B14 or A55 were induced with 2 µg/ml 614 
doxycycline for 24 h, starved for 6 h in DMEM with no supplements and left 615 
unstimulated, or stimulated with TNFΑ for 18 h. Levels of secreted CXCL10 in the 616 
cell culture medium were assayed by ELISA. Data shown are representative of 2 617 
independent experiments carried out in triplicate. Statistical significance compares 618 
C6 stimulated with B14 or A55. (E) T-REx cell lines inducibly expressing B14 or A55 619 
were induced with 2 µg/ml doxycycline for 22.5 h and left unstimulated or stimulated 620 
with 20 ng/ml TNFΑ for 1.5 h in DMEM with no supplements. IL-8 expression levels 621 
were analysed by RT-qPCR relative to GAPDH. Data presented are representative 622 
of 2 independent experiments carried out in triplicate. Statistical significance, C6 623 
stimulated vs A55 stimulated. (F, G). A55 does not inhibit MAPK or JAK-STAT 624 
signalling. HEK293T cells were transfected with (F) pAP-1-Luc or (G) pISRE-Luc and 625 
pRL-TK (Methods) and plasmids ex-pressing Flag-tagged KLHL12, C6 or A55 or 626 
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empty vector (EV). After 24 h cells were stimulated with (F) 10 ng/ml PMA or (G) 627 
1000 U/ml IFNα for 6 h. Cell lysates were prepared and the fold increase in 628 
luciferase activity relative to Renilla activity was determined. In parallel, cell lysates 629 
were analysed by SDS-PAGE and immunoblotting with anti-Flag or anti-α-tubulin to 630 
determine protein expression levels from unstimulated samples. Data are 631 
representative of three independent experiments. Statistical significance compares 632 
EV stimulated with test sample.   633 
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Fig. 2. A55 inhibits NF-κB activation downstream of p65 release. HEK293T cells were 634 
transfected with pLuc-NF-κB and pRL-TK together with plasmids expressing Flag-tagged 635 
KLHL12, B14 or A55 or EV and either (A) TRAF6, (B) TRAF2, (C) TAK1, or (D) IKKβ. After 636 
24 h the fold difference in luciferase activity was determined and the abundance of indicated 637 
proteins was measured by SDS-PAGE and immunoblotting. (E) Cells were transfected with 638 
reporters as above together with a Flag-tagged p65 expression plasmid and increasing 639 
doses of plasmid expressing A55 (25, 75, 150 ng). Experiments are representative of 3 640 
independent experiments carried out in quadruplicate. Statistical significance compares EV 641 
stimulated with test sample stimulated.  642 
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Fig. 3. A55 acts downstream of IκBα degradation and prevents phosphorylation of p65 on 643 
Ser276. HEK293T-REx cell lines inducibly expressing B14, or A55, or empty vector (EV) 644 
were induced with 2 µg/ml doxycycline for 24 h and then stimulated with 40 ng/ml TNFα for 645 
20 min. The levels of IκBα, Flag-tagged B14 or A55, and α-tubulin were determined by SDS-646 
PAGE and immunoblotting. (B) The level of IκBα relative to tubulin was quantified by 647 
densitometry from 3 independent experiments. Statistical significance compares EV 648 
stimulated with B14 or A55 stimulated conditions. (C). HEK293T-REx cell lines inducibly 649 
expressing A55 or EV were induced with doxycline as in (A) and then left unstimulated (0) or 650 
stimulated with 40 ng/ml TNFα for 30 or 60 min. The levels of indicated proteins and 651 
phosphorylation of p65 were determined by SDS-PAGE and immunoblotting. Loading and 652 
p65 levels were controlled for using anti-tubulin and anti-p65, respectively. The immunoblot 653 
shown is representative of 3 independent experiments.  654 
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Fig. 4 A55 inhibits p65 nuclear translocation. (A) Representative immunofluorescent staining 655 
of p65 localisation in HeLa cells transfected with 1000 ng / well of a 6-well plate of plasmids 656 
encoding Flag-tagged B14, A55, C6 or EV and left untreated or stimulated with 20 ng/ml 657 
TNFα for 30 min. Cells were stained with DAPI (blue), anti-Flag (red) and anti-p65 (green) 658 
antibodies. (B) Percentage of transfected cells with nuclear p65. Representative of 3 659 
independent experiments, carried out in triplicate, counting 100 cells per sample. Statistical 660 
significance compares EV stimulated with A55, B14, or C6 stimulated. Scale bars, 10 μM.  661 
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Fig. 5. A55 targets host importin KPNA2. (A-C) Representative immunoblots showing (A-B) 662 
anti-Flag, or (C) anti-HA immunoprecipitation (IP) of cleared lysates from HEK293T cells 663 
lysed in (A-B) NP40 or RIPA (C) buffer and subjected to SDS-PAGE and immunoblotting 664 
with stated antibodies. (A) HEK293T cells were transfected with plasmids encoding Flag-665 
KPNA1, KPNA2, KPNA3 or EV and 24 h later cells were infected with WT VACV at 5 666 
p.f.u./cell for 18 h. (B) HEK293T-REx cells inducibly expressing B14, A55 or EV were 667 
induced with 2 µg/ml doxycline for 36 h. (C) pCW57 cell lines expressing B14 or A55 668 
inducibly were induced with 2 μg/ml doxycycline for 24 h and then transfected with a plasmid 669 
encoding HA-tagged p65. Input, cleared cell lysate; IP, immunoprecipitate. IB, immunoblot. 670 
In the right panel, the amount of KPNA2 co-precipitating with p65 in the presence of A55 or 671 
B14 was quantified by densitometry. Average of 3 independent experiments. (D) 672 
Endogenous KPNA2 levels in cell lysates from HeLa cells infected for 3, 6, or 9 h with vA55, 673 
vΔA55 or vΔA55Rev at 5 p.f.u/cell or left non-infected (NI). Tubulin was used as a loading 674 
control and VACV protein D8 as a control for infection. The immunoblot shown is 675 
representative of 2 independent experiments.   676 
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Fig. 6. A55 inhibits NF-κB activation in a cullin-3-independent manner via its Kelch domain. 677 
(A) Immunoblots following immunoprecipitation (IP) of cleared cell lysates from HEK293T-678 
REx cells inducibly expressing (A) B14, A55 or EV, (B) B14 or A55, (C) B14, A55, A55-BTB, 679 
A55-Kelch, or EV, 24 h post induction with 2 μg/ml doxycycline and lysis in NP40 (A and D) 680 
or RIPA (B) lysis buffer. Samples were subjected to SDS-PAGE and immunoblotting with the 681 
stated antibodies. (A and D) Flag-tagged immunoprecipitation and immunoblotting for 682 
endogenous cullin-3. (B) Reciprocal IP with protein G-Sepharose supplemented with mouse 683 
anti-Myc using cell lysates prepared 24 h post-transfection with pCDNA-Myc-CUL3 or CUL5. 684 
(C) Schematic of A55 domains. Full length A55 from amino acid 1 to 565 was divided into 685 
the N-terminal BTB-BACK containing domain and the C-terminal Kelch domain as depicted. 686 
(E) Flag IP as with (D) in RIPA buffer using the pCW57 HEK cell lines expressing B14, A55, 687 
A55-BTB or A55-Kelch and blotting for endogenous KPNA2. Input, cleared lysate; IP, 688 
immunoprecipitate; IB, immunoblot. *, antibody heavy/light chain. (F) HEK293T cells were 689 
transfected with pLuc-NF-κB and pRL-TK together with 100 ng pcDNA3-Flag-KLHL12, 20 ng 690 
pcDNA4-coB14R-Flag, 100 ng pcDNA4/TO-nTAP-coA55R, pcDNA4/TO-nTAP-coA55R-691 
BTB, pcDNA4/TO-nTAP-coA55R-Kelch or pcDNA4/TO-EV. In the right panel cells were also 692 
transfected with plasmid expressing TRAF6. After 24 h cells were either left unstimulated or 693 
stimulated with 15 ng/ml IL-1β for 6 h and the luciferase and renilla activity were measured. 694 
Statistical significance compared EV (stimulated) with test samples. (G). Lysates from cells 695 
treated (as in F, left panel) were analysed by SDS-PAGE and immunoblotting with the 696 
indicated antibodies. Data shown in all panels are representative of 3 independent 697 
experiments.  698 
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Fig. 7. The A5 Kelch domain inhibits p65 nuclear translocation. (A) Representative 699 
immunofluorescent staining of p65 localisation in HeLa cells transfected with plasmids 700 
encoding Flag-tagged B14, A55, C6 or EV and left untreated or stimulated with 40 ng/ml 701 
TNFα for 30 min. Cells were stained as described in Methods with DAPI (blue), anti-Flag 702 
(red) and anti-p65 (green). Scale bars, 20 μM. (B) Percentage of transfected cells with 703 
nuclear p65. Representative of 3 independent experiments. Statistical significance compares 704 
EV (stimulated) with A55, B14, or C6 (stimulated). (C) Representative image of HeLa cells 705 
transfected with a plasmid encoding A55-BTB. Scale bar, 10 μM. Representative of 3 706 
independent experiments.   707 
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Fig. 8. Infection with vΔA55 induces enhanced CD8+ T-cell response. Female C57/Bl6 mice 708 
(6-8 weeks old, n=5) were injected intradermally in the ear pinnae with 5 x 103 p.f.u. of 709 
purified vA55, vΔA55 or vΔA55Rev, or PBS. At 7 d p.i. the total number of cells in (A) spleen 710 
and (B) draining lymph node (DLN) were determined. The absolute number of CD8+ or CD4+ 711 
T-cells from spleen (A) or DLN (B), and the number of splenic NK cells, macrophages, and 712 
neutrophils (A) were determined by FACs. The expression of CD69 on (C) splenic NK, CD4+ 713 
and CD8+ cells and on (D) DLN CD4+ and CD8+ cells was quantified. (E) Number of splenic, 714 
VACV-specific, DimerX positive CD8+ T cells at day 7 and 28 p.i. Statistical analysis 715 
compares vΔA55 with vA55 or vA55Rev. Data shown are representative of 2 independent 716 
experiments.  717 
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Fig. 9. Infection with vΔA55 induces enhanced CD8+ T cell cytotoxicity and better protection 718 
to VACV challenge. Mice were infected as in Fig. 7 and the immune response was analysed 719 
at 28 d p.i. (A) 51Cr-release assay assessing the ability of splenic CD8+ T cells to lyse VACV-720 
infected EL4 cells, or splenic NK cells to lyse VACV-infected P815 cells. Data are presented 721 
as percentage cell lysis at various effector to target (E:T) cell ratios. (B) 51Cr-release assay 722 
conducted as in (A) but pre-incubated with a monoclonal anti-CD8 antibody. (C and D). At 28 723 
d p.i. with vA55, vΔA55 or vΔA55Rev immunised mice were infected with 107 p.f.u. of WT 724 
VACV and the weight change (C) and pulmonary virus titres (D) were determined. Statistical 725 
analysis compares vΔA55 with vA55 or vA55Rev. Data shown are representative of 2 726 
independent experiments. 727 
  728 
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Mammalian expression vector with N-terminal or C-terminal STREPI and 
STREPII tag followed by Flag tag or with a C-terminal HA tag only or a C-





























































































N/A N/A Addgene, 19893 
pcDNA3-Flag-
CUL5 
N/A N/A Addgene, 19895 
M5P-Flag Mammalian expression vector with Flag tag under the control of the Murine 






N/A N/A Gift, Andrew Bowie 
pCW57-GFP-
P2A-MCS 
Lentiviral expression plasmid with GFP in MSC1 and P2A skip sequence 












































pCMV-PACK Packaging plasmid for lentivirus production with HIV Gag, Pol, Rev and Tat 
under the CMV promotor, Amp
r
 
Gift, Dr. H. Laman 




Gift, Dr. H. Laman 
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pLDT-MCS Lentiviral expression plasmid with expression under the control of a 
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pCAGGS-Flag-
KPNA1 
N/A N/A (31) 
pCAGGS-Flag-
KPNA2 
N/A N/A (31) 
pCAGGS-Flag-
KPNA3 




, Ampicillin resistance; Puro
r
, Puromycin resistance; Neo
r
, Neomycin resistance; Zeo
r
, Zeocin resistance; 731 
Blast
r
, Blasticidin resistance. 732 









